207 related articles for article (PubMed ID: 18166777)
1. Myelodysplastic/myeloproliferative disorders.
Malcovati L; Cazzola M
Haematologica; 2008 Jan; 93(1):4-6. PubMed ID: 18166777
[No Abstract] [Full Text] [Related]
2. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Cross NCP; Godfrey AL; Cargo C; Garg M; Mead AJ;
Br J Haematol; 2021 Nov; 195(3):338-351. PubMed ID: 34409596
[No Abstract] [Full Text] [Related]
3. Phenotype and genotype in the myeloproliferative disorders.
Spivak JL
Eur J Haematol Suppl; 2007 Oct; (68):9-12. PubMed ID: 17727558
[No Abstract] [Full Text] [Related]
4. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation.
Hussein K; Theophile K; Buhr T; Beller A; Kreipe H; Bock O
Br J Haematol; 2009 Jun; 145(5):673-5. PubMed ID: 19344408
[No Abstract] [Full Text] [Related]
5. Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations.
Vannucchi AM; Guglielmelli P
Haematologica; 2008 Jul; 93(7):972-6. PubMed ID: 18591622
[No Abstract] [Full Text] [Related]
6. [Clinical aspects of myeloproliferative disorders excluding CML].
Komatsu N
Rinsho Ketsueki; 2008 Oct; 49(10):1411-9. PubMed ID: 18833926
[No Abstract] [Full Text] [Related]
7. Myelodysplasia and myeloproliferative disorders in childhood: an update.
Emanuel PD
Br J Haematol; 1999 Jun; 105(4):852-63. PubMed ID: 10554793
[No Abstract] [Full Text] [Related]
8. Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood.
Lasky J; Sakamoto KM
MedGenMed; 2005 Mar; 7(1):21. PubMed ID: 16369326
[No Abstract] [Full Text] [Related]
9. The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
Kremer M; Horn T; Dechow T; Tzankov A; Quintanilla-Martínez L; Fend F
Leukemia; 2006 Jul; 20(7):1315-6. PubMed ID: 16617316
[No Abstract] [Full Text] [Related]
10. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
11. Focus on myeloproliferative diseases and myelodysplastic syndromes.
Van Etten RA; Shannon KM
Cancer Cell; 2004 Dec; 6(6):547-52. PubMed ID: 15607959
[No Abstract] [Full Text] [Related]
12. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
Ghaderi M; Strömberg O; Porwit A
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
[TBL] [Abstract][Full Text] [Related]
13. Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
Ohyashiki K; Ohyashiki JH
Leukemia; 2006 Jul; 20(7):1297-8. PubMed ID: 16617315
[No Abstract] [Full Text] [Related]
14. Myeloid neoplasms with isolated del(5q) and
Sangiorgio VFI; Geyer JT; Margolskee E; Al-Kawaaz M; Mathew S; Tam W; Orazi A
Haematologica; 2020 Jun; 105(6):e276-e279. PubMed ID: 31558664
[No Abstract] [Full Text] [Related]
15. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms.
Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Siragusa S; Hanson CA; Pardanani A; Tefferi A
Leukemia; 2010 Apr; 24(4):859-60. PubMed ID: 20111067
[No Abstract] [Full Text] [Related]
16. The JAK2 V617F mutation is rare in RARS but common in RARS-T.
Ceesay MM; Lea NC; Ingram W; Westwood NB; Gäken J; Mohamedali A; Cervera J; Germing U; Gattermann N; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
Leukemia; 2006 Nov; 20(11):2060-1. PubMed ID: 16932338
[No Abstract] [Full Text] [Related]
17. The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis.
Yip SF; So CC; Chan AY; Liu HY; Wan TsK; Chan LC
Leukemia; 2006 Jun; 20(6):1165. PubMed ID: 16572200
[No Abstract] [Full Text] [Related]
18. [Molecular mechanisms in myeloproliferative diseases and myelodysplastic syndromes].
Harada H; Harada Y; Kimura A
Nihon Rinsho; 2009 Oct; 67(10):1901-5. PubMed ID: 19860187
[TBL] [Abstract][Full Text] [Related]
19. MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 x 10(9)/l.
Zipperer E; Wulfert M; Germing U; Haas R; Gattermann N
Ann Hematol; 2008 May; 87(5):413-5. PubMed ID: 18040685
[No Abstract] [Full Text] [Related]
20. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
